Fighting the War Against Obesity

Share Article

A new informative web site on Rimonabant allows consumers to read about and discuss their experiences with the Rimonabant series of drugs.

Encouraging open discussion about its medication, the Rimonabant Information web site (available online at provides extensive details and resources for consumers.

"It is often extremely useful for patients to read about their medication, and to learn from each other, whether it is to share experiences or to lend support," says Scott Smith of Rimonabant Information. "Our new Rimonabant Information web site lends itself to exactly that kind of healthy interaction."

Rimonabant is the active chemical in the Acomplia range of medication. Acomplia battles obesity by blocking specific receptors in the brain and fat tissues, and it is an effective adjunct to diet and exercise. Acomplia is already available in several countries outside the United States.

Another prospective product in the war against obesity, Taranabant, is in trial, with the intention of developing a drug that is fewer side effects that any other obesity drug on the market.

"Obesity problems in developed nations continue to grow at a frightening pace, and we want to prove that these problems can fought," says Smith. "Our web site takes the battle to another level, allowing people to band together in the war against obesity."


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Smith

Email >